Skip to main content
. Author manuscript; available in PMC: 2015 Apr 9.
Published in final edited form as: Sci Transl Med. 2012 Sep 5;4(150):150ra123. doi: 10.1126/scitranslmed.3003936

Fig. 6.

Fig. 6

MIV-150 EVA-40 IVRs offer significant protection against SHIV-RT infection. (A) Infection frequency across the placebo and different 100-mg MIV-150 IVR groups. (B) Infection frequency evaluating only the role of post-challenge IVR exposure. In (A) and (B), the numbers above each bar indicate the number of infected animals over the number of challenged animals. Fisher's exact test was used for statistical analysis. (C) Viremia (SIV RNA copies per milliliter of plasma) over time for each animal challenged with 103 TCID50 SHIV-RT after receiving placebo or MIV-150 IVRs with different timing of insertion and removal. (D) Mean ± SEM plasma viral load of infected animals in each group.